Functional characterization of a novel somatic mutation of PIK3CB Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ Signal Transduction and Targeted Therapy 2017, volume 2, 17063
Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study. This is the Company’s second […]
Oxford, UK, 4 August 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its COO/CSO will be delivering two presentations at the CHI DoT 11th Annual Kinase Inhibitor Discovery conference, Boston, 27 and 28 September 2017. The presentation on Wednesday 27 September by Stephen […]
Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its Chief Scientific Officer will be delivering a presentation at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design Congress, Berlin, 13 June 2017. Stephen Shuttleworth, COO & […]
Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma. Jain N., Seghal L., Shuttleworth S.J., Samaniego F. Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2366.